COMMUNIQUÉS West-GlobeNewswire

-
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
24/04/2024 - 13:00 -
First Wave BioPharma Announces Invited Paper for Special Edition on Celiac Disease in Peer-Reviewed Scientific Journal, Nutrients
24/04/2024 - 13:00 -
Treace Medical Named First Medical Device Partner and Official Foot and Ankle Solution Partner of the PPA Tour
24/04/2024 - 13:00 -
LSL Pharma Group Secures $3.8 Million as the Second and Final Tranche of Its Private Placement of Units
24/04/2024 - 13:00 -
Augmedix Launches Industry’s First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments
24/04/2024 - 13:00 -
Sharecare to report first quarter fiscal 2024 financial results on Thursday, May 9
24/04/2024 - 13:00 -
Good Supply Cannabis Introduces New Signature ‘Bud Squad’ Products
24/04/2024 - 13:00 -
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
24/04/2024 - 13:00 -
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
24/04/2024 - 13:00 -
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
24/04/2024 - 10:05 -
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24/04/2024 - 10:00 -
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24/04/2024 - 10:00 -
Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair
24/04/2024 - 09:00 -
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
24/04/2024 - 08:00 -
Pharming Group to report first quarter 2024 financial results on May 8
24/04/2024 - 08:00 -
Vistin Pharma ASA: First quarter 2024 financial results
24/04/2024 - 07:44 -
Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent
24/04/2024 - 07:30 -
Nicox : Deuxième convocation à l’Assemblée Générale Ordinaire et Extraordinaire le 6 mai 2024 et désignation d’un mandataire ad hoc
24/04/2024 - 07:30 -
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
24/04/2024 - 07:00
Pages